DOI QR코드

DOI QR Code

Bioequivalence of Rispen Tablet to Risperdal Tablet (Risperidone 2 mg)

리스페달 정(리스페리돈 2mg)에 대한 리스펜 정의 생물학적 동등성

  • Cho, Hea-Young (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Park, Eun-Ja (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Kang, Hyun-Ah (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Baek, Seung-Hee (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Lee, Suk (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Park, Chan-Ho (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University) ;
  • Moon, Jai-Dong (Medical School, Chonnam National University) ;
  • Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
  • 조혜영 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 박은자 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 강현아 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 백승희 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 이석 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 박찬호 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 문재동 (전남대학교 의과대학) ;
  • 이용복 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소)
  • Published : 2004.04.20

Abstract

The purpose of the present study was to evaluate the bioequivalence of two risperidone tablets, Risperdal (Janssen Korea Co., Ltd.) and Rispen (Myung In Pharm. Co., Ltd), according to the guidelines of Korea Food and Drug Administration (KFDA). The risperidone release from the two risperidone formulations in vitro was tested using KP VIII Apparatus II method with various of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four healthy male subjects, $23.33\;{\pm}2.10$ years in age and $69.24{\pm}8.05\;kg$ kg in body weight, were divided into two groups and a randomized $2\;{\times}\;2$ cross over study was employed. After one tablet containing 2 mg as risperidone was orally administered, blood was taken at predetermined time intervals and the concentrations of risperidone in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t$,$C_{max},\;and\;T_{max}$ were calculated and ANOVA test was utilized for the analysis of the parameters using logarithmically transformed $AUC_t$,$C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the Risperdal were 0.20, -1.29 and -11-09% for $AUC_t$,$C_{max},\;and\;T_{max}$, respectively There were no sequence effects two formulations in parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g.,$log(0.90){\sim}log(1.30)$ and $log(0.84){\sim}log(1.09)$ for$AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA guideline for the bioequivalence were satisfied, indicating Rispen tablet and Risperdal tablet were bioequivalent.

Keywords

References

  1. G. Mannens, M. Huang, W. Meuldermans, J. Hendricks, R. Woestenborghs and J. Heykants, Absorption, metabolism and excretion of risperidone in humans, Drug Metab. Disposit, 21, 1134-1141 (1993)
  2. PDR$^{\circledR}$ 53 editions 1999, pp. 1432-1436 (1999)
  3. 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험 기준 (2002.11.22)
  4. 식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000.1.4)
  5. R. Woestenborghs, W. Lorreyne, F.V. Rompaey and J. Heykants, Determination of risperidone and 9-hydroxyri-speridone in plasma, urine and animal tissues by highperformance liquid chromatography, J. Chromatogr. B, 583, 223-230 (1992) https://doi.org/10.1016/0378-4347(92)80556-6
  6. O.Y. Olesen and K. Linnet, Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs, J. Chromatogr. B, 698, 209-216 (1997) https://doi.org/10.1016/S0378-4347(97)00302-2
  7. Statistical Solutions Ltd., Equiv Test$^{\circledR}$ 1.0, U.K. (1998)
  8. Food and Drug Administration (FDA): Guidance for Industry; Waiver of in vivo bioavailability and bioequivalence study for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Center for Drug Evaluation and Research (CDER), August (2000)